AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
1-Year Return
29.75%
This Quarter Return
+4.09%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$306M
AUM Growth
+$52M
(+20%)
Cap. Flow
+$60.2M
Cap. Flow
% of AUM
19.68%
Top 10 Holdings %
Top 10 Hldgs %
50.4%
Holding
90
New
22
Increased
27
Reduced
12
Closed
13
Top Buys
| 1 |
Apogee Therapeutics
APGE
|
$22.3M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$13.4M |
| 3 |
Xenon Pharmaceuticals
XENE
|
$8.2M |
| 4 |
Krystal Biotech
KRYS
|
$6.67M |
| 5 |
Arcellx
ACLX
|
$6.23M |
Top Sells
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$12.3M |
| 2 |
Biogen
BIIB
|
$11.4M |
| 3 |
Ventyx Biosciences
VTYX
|
$3.3M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$2.97M |
| 5 |
FibroGen
FGEN
|
$2.65M |
Sector Composition
| 1 | Healthcare | 94.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
FibroGen
FGEN
$45.7M
| – | – |
-39,332
| Closed | -$2.65M |
|
77
Jasper Therapeutics
JSPR
$43.7M
| – | – |
-47,695
| Closed | -$653K |
|
|
MESO
78
Mesoblast
MESO
$1.73B
| – | – |
0
| – | – |
|
79
Mineralys Therapeutics
MLYS
$2.2B
| – | – |
-62,500
| Closed | -$1.07M |
|
80
Vir Biotechnology
VIR
$714M
| – | – |
-20,000
| Closed | -$491K |
|
81
Viridian Therapeutics
VRDN
$1.52B
| – | – |
0
| – | – |
|
|
82
Ventyx Biosciences
VTYX
$185M
| – | – |
-100,696
| Closed | -$3.3M |
|
|
WHWK
83
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| – | – |
-187,675
| Closed | -$1.28M |
|
|
VINC
84
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| – | – |
-74,639
| Closed | -$1.94M |
|
|
ALPN
85
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| – | – |
-118,891
| Closed | -$1.22M |
|
|
RETA
86
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-29,105
| Closed | -$2.97M |
|
|
KDNY
87
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – |
-321,017
| Closed | -$12.3M |
|